Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Sep 3;34(177):240280.
doi: 10.1183/16000617.0280-2024. Print 2025 Jul.

Air pollution and alveolar health

Affiliations
Review

Air pollution and alveolar health

Carmelo Sofia et al. Eur Respir Rev. .

Abstract

Exposure to air pollution has been associated with up to 9 million premature deaths per year worldwide, with the respiratory system a key site for its effects. Air pollution exposure is a well-established risk factor for the development and exacerbation of airways diseases and lung cancer, however relatively little is known regarding the risks associated with air pollution interacting with areas of gas exchange - the alveoli and pulmonary interstitium. In recent years, evidence has emerged identifying a role in the development and progression of sub-clinical interstitial lung abnormalities as well as progression and risk of exacerbation of fibrotic interstitial lung diseases. This review outlines the epidemiologic evidence that air pollution perturbs alveolar health. It considers the different components of ambient air pollution, how penetration to the alveoli is determined by particle size and whether the response to alveolar exposure may be modulated by personal susceptibility factors. We discuss potential acute and chronic pathogenic mechanisms of injury upon the pulmonary interstitium and how these may contribute to the development and/or progression of interstitial processes. Finally, we explore current knowledge gaps and the potential for air pollution interventions in vulnerable individuals to support alveolar homeostasis and so prevent disease development and/or progression.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: C. Sofia has nothing to disclose. J.G.H. Parkin reports grants from Wessex Medical Research and is a named post-doctoral researcher on M. Loxham's BBSRC David Phillips Fellowship. J.A. Bell reports support for the present study from NIHR Southampton Biomedical Research Centre, grants from AAIR charity and NIHR Southampton Biomedical Research Centre, and support for attending meetings from the European Respiratory Society. L.S.N. Dean reports support for the present study from AXA Research fund. L.J. Edgeway, L. Sayer and N.H.C. Easton have nothing to disclose. D.E. Davies reports grants from Boehringer Ingelheim, consultancy fees from Synairgen, a leadership role with Asthma Allergy and Inflammation Research Charity, and stock (or stock options) with Synairgen. B.G. Marshall has nothing to disclose. S.T. Holgate reports grants from UKRI Clean Air Champion, University Grant and NERC Council Member, consultancy fees from Dyson, Healthy Air Technologies Ltd, participation on a data safety monitoring board or advisory board with Dyson, Healthy Air Technologies Ltd, a leadership role with RCP Special Advisor on Air Quality, DEFRA Advisor on Air Quality Information Systems (AQIS), NE Board Director, Synairgen, and stock (or stock options) with Synairgen, and the following financial (or non-financial) interests: Synairgen. L. Richeldi reports grants from Boehringer Ingelheim and Italian Drug Agency, consultancy fees from Biogen, Celgene, Boehringer Ingelheim, Bristol Myers Squibb, Pliant Therapeutics, BMS, CSL Behring, FibroGen, Veracyte and Chiesi, payment or honoraria for lectures, presentations, manuscript writing or educational events from Boehringer Ingelheim, Zambon and Chiesi, support for attending meetings from Boehringer Ingelheim and Roche, and participation on a data safety monitoring board or advisory board with Roche, Boehringer Ingelheim, FibroGen and Promedior. M.G. Jones reports grants from the Medical Research Council, Asthma+Lung UK, Royal Society, AAIR Charity and Boehringher Ingelheim, and consultancy fees from Skyhawk Therapeutics. M. Loxham reports support for the present study from BBSRC David Phillips Fellowship (BB/V004573/1), grants from BBSRC Future Leader Fellowship (BB/P011365/1), Academy of Medical Sciences Springboard award, MRC Studentship (code 2746858), Asthma, Allergy, and Inflammation Research (AAIR) Charity UK, Wessex Medical Research and Gerald Kerkut Charitable Trust, support for attending meetings from British Thoracic Society, and is a Member of the UK expert Committee on the Medical Effects of Air Pollution.

Figures

FIGURE 1
FIGURE 1
Sources of air pollution at different locations within the respiratory tree. a) Summary of potential sources of air pollution including particulate matter by size fraction, ground-level ozone (O3) and nitrogen dioxide (NO2). b) Penetration of different air pollution sources identified in a) to sites within the respiratory tree. Both composition and size influence particulate matter penetration, with only particulate matter with aerodynamic diameter <2.5 μm typically capable of reaching the alveolar region. c) Overview of potential mechanisms of alveolar homeostasis perturbation by air pollution sources including oxidative stress, DNA damage, release of proinflammatory mediators, recruitment of inflammatory cells and translocation to the pulmonary capillaries. Figure created in BioRender (https://BioRender.com/mo0n0l0).
FIGURE 2
FIGURE 2
Proposed mechanisms of injury of the alveolus by particulate matter (PM). Innate immune cells are recruited to the alveolus to phagocytose PM particles, whilst oxidative stress, epigenomic alterations and local inflammation may promote type II alveolar epithelial cells to undergo apoptosis and/or cellular senescence. Cumulative exposures may lead to the shortening of telomeres, whilst dysregulation of epithelial–mesenchymal crosstalk may promote activation of fibroblasts and pro-fibrogenic mediators. Figure created in BioRender (https://BioRender.com/pix26ud).

References

    1. Schraufnagel DE, Balmes JR, Cowl CT, et al. Air pollution and noncommunicable diseases: a review by the forum of international respiratory societies’ environmental committee, part 1: the damaging effects of air pollution. Chest 2019; 155: 409–416. doi: 10.1016/j.chest.2018.10.042 - DOI - PMC - PubMed
    1. Schraufnagel DE, Balmes JR, Cowl CT, et al. Air pollution and noncommunicable diseases: a review by the forum of international respiratory societies’ environmental committee, part 2: air pollution and organ systems. Chest 2019; 155: 417–426. doi: 10.1016/j.chest.2018.10.041 - DOI - PMC - PubMed
    1. World Health Organization . Ambient (outdoor) air pollution. Date last updated: 24 October 2024. Date last accessed: 22 July 2025. www.who.int/news-room/fact-sheets/detail/ambient-(outdoor)-air-quality-a...
    1. Burnett R, Chen H, Szyszkowicz M, et al. Global estimates of mortality associated with long-term exposure to outdoor fine particulate matter. Proc Natl Acad Sci USA 2018; 115: 9592–9597. doi: 10.1073/pnas.1803222115 - DOI - PMC - PubMed
    1. Lelieveld J, Pozzer A, Pöschl U, et al. Loss of life expectancy from air pollution compared to other risk factors: a worldwide perspective. Cardiovasc Res 2020; 116: 1910–1917. doi: 10.1093/cvr/cvaa025 - DOI - PMC - PubMed

MeSH terms

LinkOut - more resources